(Sharecast News) - Merck said on Wednesday that it has agreed to buy Terns Pharmaceuticals, a clinical-stage oncology company, for $6.7bn.
Under the terms of the deal, Merck will pay $53 per share in cash.

Terns' lead candidate, TERN-701, is a novel investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor (TKI)...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE